Risk for Guillain-Barré Syndrome Associated With Early Life Immune-Mediated Disorders
Guillain-Barré syndrome is typically associated with an acute infection.
High-dose intravenous immunoglobulin therapy was administered to all patients and may have contributed to neutralization of eculizumab.
ACE-083 is currently being studied in a Phase 2 trial for FSHD and another for Charcot-Marie-Tooth (CMT) disease.
The investigators suggest that the recruited participants may have reached a plateau in symptoms, which may have decreased the chances of additional improvement with belimumab treatment.